New hope for japanese blood cancer patients: targeted drug shows promise in early trial

NCT ID NCT03198650

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 24 times

Summary

This study tests a drug called acalabrutinib in Japanese adults with advanced B-cell blood cancers. The drug works by blocking a protein that helps cancer cells grow. The main goal is to check safety and side effects, and to see how well the drug works. About 35 people will take part in three phases of the study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Chiba, 260-8717, Japan
Research Site

Chūōku, 104-0045, Japan
Research Site

Fukuoka, 812-8582, Japan
Research Site

Isehara-shi, 259-1193, Japan
Research Site

Izumo-shi, 693-8501, Japan
Research Site

Matsuyama, 791-0280, Japan
Research Site

Nagoya, 460-0001, Japan
Research Site

Nagoya, 464-8681, Japan
Research Site

Niigata, 951-8520, Japan
Research Site

Okayama, 700-8558, Japan
Research Site

Sapporo, 060-8638, Japan
Research Site

Sendai, 980-8574, Japan
Research Site

Shimotsuke-shi, 329-0498, Japan
Research Site

Suita-shi, 565-0871, Japan

Conditions

Explore the condition pages connected to this study.

PART1: ADVANCED B-CELL MALIGNANCIES PART1: ADVANCED B-CELL MALIGNANCIES PART2: R/RCLL AND R/RMCL PART3: UNTREATED CLL